Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-labeled, Multi-center, Randomized, Prospective Phase III Study Comparing CMAB304 in Combination With CHOP to CHOP Alone With CMAB304 Maintenance in Patients With DLBCL

NCT01459887 is registered in ClinicalTrials.gov with Shanghai CP Guojian Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01459887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01459887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-labeled, Multi-center, Randomized, Prospective Phase III Study Comparing CMAB304 in Combination With CHOP to CHOP Alone With CMAB304 Maintenance in Patients With DLBCL
Lead sponsor
Shanghai CP Guojian Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2006
Completion date
February 28, 2011
Enrollment
278 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma